Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tabimorelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR known ✓ | Q92847 | 8/20 | 0.65 |
| ▸ | FCER2 | P06734 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tabimorelin SCHEMBL29440097 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| SCHEMBL6316837 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL29899698 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL209442 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL13575741 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL209441 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| SCHEMBL6316843 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL7982376 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL4435323 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 | |
| Tabimorelin SCHEMBL22345096 | 1.00 | GHSR (0.65) | GHSRFCER2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022226116-A1 | GHRELIN TREATMENT OF BRAIN DYSFUNCTION DUE TO VIRAL INFECTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2022-10-27 | — | — | WO | disclosed |